CA3246544A1 - Humanized Anti-CD45 Antibodies - Google Patents

Humanized Anti-CD45 Antibodies

Info

Publication number
CA3246544A1
CA3246544A1 CA3246544A CA3246544A CA3246544A1 CA 3246544 A1 CA3246544 A1 CA 3246544A1 CA 3246544 A CA3246544 A CA 3246544A CA 3246544 A CA3246544 A CA 3246544A CA 3246544 A1 CA3246544 A1 CA 3246544A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
chain variable
variable region
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246544A
Other languages
English (en)
French (fr)
Inventor
Lequn ZHAO
Helen KOTANIDES
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of CA3246544A1 publication Critical patent/CA3246544A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3246544A 2022-03-24 2023-03-24 Humanized Anti-CD45 Antibodies Pending CA3246544A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263323257P 2022-03-24 2022-03-24
US63/323,257 2022-03-24
US202263405237P 2022-09-09 2022-09-09
US63/405,237 2022-09-09
US202263407979P 2022-09-19 2022-09-19
US63/407,979 2022-09-19
PCT/US2023/064941 WO2023183927A2 (en) 2022-03-24 2023-03-24 Humanized anti-cd45 antibodies

Publications (1)

Publication Number Publication Date
CA3246544A1 true CA3246544A1 (en) 2023-09-28

Family

ID=88102093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246544A Pending CA3246544A1 (en) 2022-03-24 2023-03-24 Humanized Anti-CD45 Antibodies

Country Status (6)

Country Link
US (2) US11981741B2 (https=)
EP (1) EP4490197A4 (https=)
JP (1) JP2025510189A (https=)
CN (1) CN119256014A (https=)
CA (1) CA3246544A1 (https=)
WO (1) WO2023183927A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118620078B (zh) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 抗人cd45ra蛋白的抗体、抗体偶联物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029636B2 (en) * 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
CN104710504B (zh) 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
CA2861003C (en) * 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
EP3297684B1 (en) 2015-05-21 2020-12-23 Actinium Pharmaceuticals, Inc. Infusion administration of conjugated monoclonal antibodies
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017155937A1 (en) 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
JP2020530280A (ja) * 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
WO2019084273A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation
WO2020132672A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
WO2020159656A1 (en) 2019-02-01 2020-08-06 Actinium Pharmaceuticals, Inc. Molecules and their derivatives directed against cd45
JP7650819B2 (ja) 2019-04-24 2025-03-25 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用
CA3137908A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
US12605472B2 (en) 2019-09-17 2026-04-21 Actinium Pharmaceuticals, Inc. Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof
WO2022040577A1 (en) 2020-08-20 2022-02-24 City Of Hope Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells

Also Published As

Publication number Publication date
EP4490197A4 (en) 2026-04-29
US11981741B2 (en) 2024-05-14
US20240301081A1 (en) 2024-09-12
JP2025510189A (ja) 2025-04-14
EP4490197A2 (en) 2025-01-15
WO2023183927A3 (en) 2023-11-09
CN119256014A (zh) 2025-01-03
US20240010744A1 (en) 2024-01-11
WO2023183927A2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CA3246544A1 (en) Humanized Anti-CD45 Antibodies
CN100522999C (zh) 抗cd20抗体及其融合蛋白和使用方法
RU2464277C2 (ru) Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника
CA2786655C (en) Novel radioimmunoconjugates that binds human cd37
IL266885B1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
AU2019234468B2 (en) Bispecific binding agents and uses thereof
JP2020507571A (ja) 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
MX2011000891A (es) Variantes estructurales de anticuerpos para caracteristicas terapeuticas mejoradas.
EP4284446A2 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
KR20230024326A (ko) 암의 치료를 위한 항-b7h3 항체
WO2024055040A2 (en) Humanized anti-cd45 antibodies
JPH07504334A (ja) Ａ３３抗原に対するヒト化抗体
TWI908815B (zh) 用於人類疾病之治療的ｃｄ３８抗體
US20150071853A1 (en) Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof
Puchol Tarazona et al. Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer
CA3208566A1 (en) Antibodies to igf2r and methods
US20250197501A1 (en) Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
TW202600607A (zh) Ｄｄｌ３結合免疫接合物及其用途
EP4469095A1 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2025214280A1 (zh) 一种放射性核素偶联物的制备方法
TW202611088A (zh) 5t4結合多肽及其用途
HK1149273A (en) Anti-cd20 antibodies and fusion proteins thereof and methods of use

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240923

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241001

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241001

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241001

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314